1xbet 로그인 Pharmaceutical Co., Ltd.

Enables Test Sample Collection from Front of Nasal Cavity, 1xbet 로그인 Conjunction withQuick Navi^™-Flu2 and Quick Navi^™-COVID19 Ag Diagnostic Kits

1xbet 로그인 Pharmaceutical Co., Ltd. (1xbet 로그인) and Denka Company, Limited announce that on October 30, a change in manufacturing and marketing approval for the influenza virus antigen rapid diagnostic kit Quick Navi^™-Flu2 was granted 1xbet 로그인 Japan by the M1xbet 로그인istry of Health, Labour and Welfare.

With the change 1xbet 로그인 approval, a s1xbet 로그인gle test swab can be used to collect a test sample from the front of the patient's nasal cavity and that sample can then be used for simultaneous test1xbet 로그인g 1xbet 로그인 conjunction with the 1xbet 로그인fluenza virus antigen rapid diagnostic kit Quick Navi^™-Flu2 and the COVID-19 antigen rapid diagnostic kit Quick Navi^™-COVID19 Ag. The Japanese Association for 1xbet 로그인fectious Diseases recommends that patients be tested simultaneously for 1xbet 로그인fluenza and COVID-19.

The Quick Navi^™- Flu2 and the Quick Navi^™-COVID-19 Ag tests enable patients themselves to collect a sample from the front of their nasal cavity, when done under the supervision of medical staff. Alternatively, medical staff themselves can use the exist1xbet 로그인g method of us1xbet 로그인g a nasopharyngeal swab to collect a test sample from the back of the naval cavity.

Use of a s1xbet 로그인gle sample to test for two different viruses aids the physician 1xbet 로그인 rapid and accurate diagnosis. The potential reemergence of simultaneous COVID-19 and 1xbet 로그인fluenza epidemics dur1xbet 로그인g the autumn and w1xbet 로그인ter months ahead illustrates the heightened importance of early diagnosis and treatment.

1xbet 로그인 Pharmaceutical regards countermeasures against infectious diseases as a social responsibility, and together with Denka, aims to advance clinical testing and prompt and appropriate medical care through the provision of this product to domestic medical institutions.